Ucb Pharma AS

Org. no. 976281918 · Oslo · Founded 1996 · 5 employees

Score · fiscal year 2023

41of 100

How to read this: the company is ahead of 38 % of companies in the Morning class Medium in the same sector in 2023. What does this mean?

Rank in the Morning class Medium: 2,048 of 3,284 · What are Morning company classes?
Place in the whole sector: 13,278 of 21,201 · Handel

Profile

Beaver · Builder

Lower profitability, lower solidity

Position against comparable companies in 2023, not a verdict on the company. Based on profitability 43 and solidity 37 out of 100 among companies in the Morning class Medium in the same sector in 2023. Methodology

Against the sector

Ucb Pharma AS is 9 points below the median for companies in the Morning class Medium in the same sector in 2023.

Median score 50 among 3,284 companies.

Against companies in the Morning class Medium in the same sector in 2023: operating margin 3.3% (median 2.9%) and equity ratio 22.3% (median 29.5%).

Source: Register of Company Accounts and Central Coordinating RegisterFetched 28 October 2026Report an issue
Key figures · 2023

The numbers behind the score

The numbers behind the score · 2023
MeasureCompanyMedianAhead of
Operating revenue228 MNOK91 MNOK
Operating margin 3.3% 2.9% 55 %
Profit margin 2.6% 2.7% shown, not part of the index
Return on assets 6.2% 11.6% 30 %
Equity ratio 22.3% 29.5% 38 %
Debt-to-equity 3.49 2.32 36 %
Current ratio 1.28 1.39 42 %
Revenue growth – 5.2% not compared
Revenue per employee45.51 MNOK4.75 MNOK

The median and “ahead of” refer to companies in the Morning class Medium in the same sector in 2023. The bar shows the share of companies the figure is ahead of.

With an index of 41, Ucb Pharma AS does better than 38% of companies in the Morning class Medium in the same sector (3,284 companies) in 2023.

Over time

Score 2023–2025

CompanyMedian0255075100202320242025
  • Ucb Pharma AS
  • Median: companies in the Morning class Medium in the same sector
Analysis · 2023

What the numbers say

Ucb Pharma AS had an operating margin of 3.3% and an equity ratio of 22.3% in 2023, and ranks 13,278 of 21,201 in Handel.

This text is generated automatically from the 2023 accounts.

Estimated value · 2023

Three simple methods

The methods give between 33 MNOK and 69 MNOK.

MethodInputMultipleEstimate
P/E Net profit: 4.4 MNOK 10.0 44 MNOK
EV/EBIT Operating profit: 7.5 MNOK
minus net debt −8.8 MNOK
8.0 69 MNOK
P/B Equity: 33.1 MNOK 1.0 33 MNOK

A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation

Indications · 2023

Worth a closer look

No rules were triggered for this year.

Indications based on the latest annual accounts from open data. Not investment or financial advice.

Financial costs were 2.8% of the debt in 2023. The policy rate averaged 3.54 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.

See interest rates, prices and exchange rates for the sector

Data quality

No anomalies found in the figures.

Stress test · 2022

Scenario analysis: the sector's weakest year

We have no accounts for 2022, the sector's weakest year, for this company.

The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology

Components · 2023

What the score is made of

Profitability43 weight 30%
Solidity37 weight 25%
Liquidity42 weight 15%
Growth– no data, left out
Consistency46 weight 15%

Index version 2. Data completeness 85%: the share of the weights that had data.

2023

Questions and answers

How profitable is Ucb Pharma AS?

The operating margin was 3.3% in 2023, against a median of 2.9% among companies in the Morning class Medium in the same sector. Return on assets was 6.2%.

How solid is Ucb Pharma AS?

The equity ratio was 22.3% in 2023 (median 29.5%). Debt-to-equity was 3.49 (median 2.32).

What is the liquidity of Ucb Pharma AS like?

The current ratio was 1.28 in 2023 (median 1.39).

How does Ucb Pharma AS compare in Handel?

Ucb Pharma AS ranks 13,278 of 21,201 in Handel for 2023. Among companies in the Morning class Medium it is number 2,048 of 3,284.

From the Central Coordinating Register

Org. no.
976281918
Legal form
AS
Sector
Handel (46.460)
Morning company class
Medium
Employees
5 registered 12 May 2025
Founded
20 March 1996 30 years in operation
Share capital
0.49 MNOK
Business address
Haakon VIIs gate 6, 0161 OSLO
Municipality
Oslo rank 63–220 of 357 in Norway
Latest accounts filed
2025

Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre

Ownership and roles

Chief executive
Fredrik Arneberg
Chair of the board
Christina Dyreborg Jeppesen
Board member
Jaana Mattila
Board member
Fredrik Arneberg
Auditor
Forvis Mazars AS
Accountant
KPMG Accounting AS
Accountant
Azets Insight AS

Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.

Owners and shareholdings will appear here once the shareholder data extract is in place.

Coming · not built yet

Error in the data?

Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.

Report an issue

Figures last fetched 28 October 2026.

Details

Year by year · 2023–2025

Key figure202320242025Trend
Index415246
Rank13,27810,54713,269
Operating margin3.3%3.4%3.3%
Return on assets6.2%7.1%6.0%
Equity ratio22.3%28.7%24.8%
Current ratio1.281.401.33
Revenue growth–9.3%5.9%

Accounts

From the Brønnøysund Register Centre, in the company's reporting currency (NOK).

Key figure202320242025
Operating revenue227.5 MNOK248.6 MNOK263.4 MNOK
Operating profit7.5 MNOK8.5 MNOK8.7 MNOK
Profit before tax5.9 MNOK5.4 MNOK5.1 MNOK
Net profit4.4 MNOK3.6 MNOK4.0 MNOK
Financial expenses3.2 MNOK4.0 MNOK5.0 MNOK
Total assets148.8 MNOK132.8 MNOK167.3 MNOK
Current assets148.6 MNOK132.7 MNOK167.3 MNOK
Equity33.1 MNOK38.1 MNOK41.4 MNOK
Retained earnings27.9 MNOK31.6 MNOK35.5 MNOK
Total liabilities115.6 MNOK94.7 MNOK125.9 MNOK
Current liabilities115.6 MNOK94.7 MNOK125.9 MNOK

Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 28 October 2026, accounts id 4950437.